Traders should monitor timing of the FDA EOP2 meeting and any partnership announcements, which could serve as near-term catalysts. The strong Day 57 data in the 200µg cohort suggests durable responses, increasing the likelihood of pivotal trial success and potential 505(b)(2) pathway approval.
Price Chart
Executive Summary
Medicus Pharma clarified its Phase 2 topline data for SkinJect-003 in nodular basal cell carcinoma, emphasizing strong activity in the 200µg dose cohort with 73% clinical clearance and 40% histological response at Day 57. The company is advancing the 200µg dose toward a registrational study and plans an End-of-Phase 2 meeting with the FDA, while downplaying the non-therapeutic device-only arm. This represents decision-grade data supporting continued development.
Key Facts
- Phase 2 data shows 73% clinical clearance and 40% histological response at Day 57 for the 200µg dose of SkinJect in nodular BCC
- The 200µg cohort demonstrated improving efficacy over time, supporting its selection as the registrational dose
- Company will focus Clinical Study Report and future development on active treatment arms, excluding device-only data from pivotal analysis
- Planned End-of-Phase 2 meeting with FDA to guide registrational trial design for SkinJect
- SkinJect targets a $2B market opportunity in non-melanoma skin cancers, including Gorlin Syndrome
Financial Impact
Non-dilutive value inflection — no immediate revenue but significant derisking of clinical asset with potential for partnerships or accelerated development
Risk Factors
- Phase 2 is a proof-of-concept study — results may not replicate in larger pivotal trials
- No definitive trial timeline or endpoints confirmed; regulatory feedback from FDA could require larger or longer studies
- Company has multiple early-stage collaborations (mRNA, AI) that are non-binding and may not materialize
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3266511 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.60 | awaiting T+1 | — | $2.41 (−7.31%) |
Oct 16, 2026 10d ago | 8-K | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.41 (−9.23%) |
Oct 16, 2026 10d ago | SC 13G/A | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.41 (−9.23%) |
Oct 7, 2026 19d ago | 8-K | $0.1019 $0.0921 | ▼ −9.62% | ▼ −10.22% | $2.41 (+2265.06%) |
Sep 14, 2026 6w ago | 8-K | $0.1593 $0.1521 | ▼ −4.52% | ▼ −4.06% | $2.41 (+1412.87%) |
Sep 11, 2026 6w ago | 8-K | $0.1626 $0.1593 | ▲ +2.03% | ▲ +1.58% | $2.41 (−1382.16%) |
Sep 10, 2026 6w ago | Press Release | $0.1614 $0.1626 | ▲ +0.74% | ▼ −0.11% | $2.41 (+1393.18%) |
Sep 3, 2026 7w ago | 8-K | $0.1705 $0.1720 | ▲ +0.88% | ▲ +1.27% | $2.41 (+1313.49%) |
Jul 16, 2026 14w ago | Press Release | $0.4060 $0.3758 | ▼ −7.44% | ▼ −6.45% | $2.41 (+493.60%) |
May 14, 2026 23w ago | Press Release | $0.3010 $0.2910 | ▲ +3.32% | ▲ +3.26% | $2.41 (−700.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers